theMednetRegister

Internal Medicine

NCI-CCC Myeloma Tumor Board Question   

Questions discussed in this category

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
1 Answer available
How do you approach the initial dosing of carfilzomib for patients with relapsed multiple myeloma?
Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?
2 Answers available
How do you approach post-transplant maintenance for patients with high-risk myeloma?
Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...
2 Answers available
How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?
1 Answer available
For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?
1 Answer available
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
2 Answers available
Which patients with smoldering myeloma do you treat?
2 Answers available
How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
2 Answers available
What is your preferred maintenance strategy for high risk multiple myeloma?
2 Answers available


Papers discussed in this category

The New England journal of medicine, 2012-05-10
Lenalidomide after stem-cell transplantation for multiple myeloma.
Nature communications, 2019-04-23
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Blood, 2012 Aug 13
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
J Clin Oncol, 2020 Apr 16
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Blood,
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
The Lancet. Oncology, 2019-01
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Blood,
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
The Lancet. Oncology, 2018-07
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Blood Cancer J, 2020 Mar 09
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
JAMA Oncol,
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Blood Cancer J, 2021 Jan 11
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
N Engl J Med,
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Blood cancer journal, 2018-06-12
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
J. Clin. Oncol., 2019 Oct 25
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
JAMA Oncol,
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Lancet Haematol,
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Leukemia, 2020 Jul 21
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Blood, 2022 Oct 20
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Kidney international, 2018-07
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.
BMC nephrology, 2019-02-14
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

Related Topics in Internal Medicine

Copyright © 2024 theMednet
All Rights Reserved.